SensoDetect (SDET) Q3 2025 earnings summary

Executive summary

• Achieved a technological breakthrough enabling rapid, scalable, and accurate ADHD diagnostics using AI-based BERA technology, with diagnostic accuracy comparable to MRI and EEG but with superior scalability and speed.

• Strengthened medical and clinical leadership with new advisors and key personnel, including Dr. Fatimah Saeed Alahmari and Dr. Mohamed Hussein Atwa Ahmed.

• Expanded internationally, winning first prize in China's "Jinying Cup" and accelerating partnerships and growth in the Chinese market.

• Transitioned to consolidated group reporting, now including Senso Detect AB, Senso Detect HK Co., Ltd., and Shengde (Shenzhen) Medical Technology Co. Ltd.

Financial highlights

• Q3 2025 net sales: 907 KSEK; net result after financial items: -2,297 KSEK; EPS: -0.005 SEK.

• Cash flow from operating activities in Q3: -1,211 KSEK; cash and cash equivalents at period end: 5,288 KSEK.

• Equity ratio as of September 30, 2025: 84%.

• For the first nine months of 2025: net sales 1,130 KSEK; net result after financial items: -6,750 KSEK; EPS: -0.02 SEK.

• Q3 revenue mainly from royalty income in China; increased costs due to expansion and R&D capitalization.

Outlook and guidance

• Recurring license revenues from the Chinese JV are now visible, with a minimum annual license income of 3.6 MSEK from 2026.

• Direct revenues in China projected at 15–17 MSEK for 2026 and 27–34 MSEK for 2027.

• 2026 expected to see full operational scaling, increased screening volumes, and commercial breakthrough in early autism detection.